METHODS: The studies included in the screening procedure were randomized controlled clinical trials (RCTs), both retrospective and prospective case-control studies, as well as in vitro and in vivo investigations. Articles were sourced from PubMed (MEDLINE), Scopus, EMBASE, Web of Science, and Google Scholar electronic databases using the following MeSH terms: (polydeoxyribonucleotide) and (bone) and (regeneration).
RESULTS: Initially, 228 articles were identified. Following the review process, a total of eight studies were ultimately examined. Among these, two were confined to laboratory studies, five were conducted on living organisms, and one encompassed both evaluations on living organisms and in vitro assessments. A descriptive qualitative approach was employed to present the data extracted from the studies that were included.
CONCLUSIONS: PDRN has the potential to enhance the process of bone healing and the quantity of newly generated bone when combined with grafting materials. Future clinical studies are warranted to ascertain the appropriate clinical application of PDRN based on the dosage under consideration.
方法:筛选程序中包含的研究是随机对照临床试验(RCTs),回顾性和前瞻性病例对照研究,以及体外和体内研究。文章来自PubMed(MEDLINE),Scopus,EMBASE,WebofScience,和GoogleScholar电子数据库使用以下MeSH术语:(聚脱氧核糖核苷酸)和(骨)和(再生)。
结果:最初,228篇文章被确认。在审查过程之后,最终检查了总共8项研究。其中,两个仅限于实验室研究,五次是在生物体上进行的,其中一项包括对生物体的评估和体外评估。采用描述性定性方法来呈现从所包括的研究中提取的数据。
结论:PDRN与移植材料结合具有增强骨愈合过程和新生成骨数量的潜力。有必要进行未来的临床研究,以根据所考虑的剂量确定PDRN的适当临床应用。